OREX-003: Phase IIa started

Orexigen began a double-blind, placebo-controlled, U.S. Phase IIa trial (OZ-101) to evaluate 10 to 20 mg of daily olanzapine plus 360 mg zonisamide SR or placebo for 10 weeks in 75 patients with schiz...